Contera Pharma will receive an upfront payment and full research funding for each target under investigation
Deal includes DTx-1252, a potential therapy for the neuromuscular disorder Charcot-Marie-Tooth disease type 1A (CMT1A), and two additional preclinical programs for other neuroscience indications
The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
Elegen is the only DNA manufacturer delivering the unique combination of complexity, length and NGS-verified accuracy within days
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
The transaction is expected to close in the first quarter of 2022
Everest gains access to a clinically validated mRNA platform and a potentially “best-in-class” mRNA COVID-19 vaccine with full technology transfer
Subscribe To Our Newsletter & Stay Updated
